Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with ITP in China

Hutchison China MediTech Limited (“Chi-Med”) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding. The first ITP patient was dosed on August 12, 2019 in China.

The study is a randomized, double-blinded, placebo-controlled Phase Ib clinical trial investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-523 in adult patients with ITP. The primary endpoint is the number of patients with any adverse event.  Approximately 50 to 60 patients will be enrolled.

- From Hutchison China MediTech Limited News Release

Read More